Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395419 | 1.00 | TDP1 (0.33) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL198107 | 1.00 | TDP1 (0.33) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL392365 | 1.00 | TDP1 (0.33) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL6239351 | 0.84 | CHRM1 (0.40) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL6240565 | 0.81 | CA2 (0.41) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL3837519 | 0.77 | TDP1 (0.42) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL687714 | 0.77 | TDP1 (0.42) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL6234803 | 0.75 | CTSS (0.34) | — | |
| SCHEMBL16667373 | 0.74 | TP53 (0.38) | OR51E2 | |
| SCHEMBL1406003 | 0.74 | TP53 (0.38) | OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521216-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2009-04-21 | — | — | US | claimed |
| US-9828594-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160355801-A1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION | 2016-12-08 | — | — | US | disclosed |
| US-9217164-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2327766-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-2319919-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1576108-B1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BASF ENZYMES LLC (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-2327767-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2327765-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-04-01 | — | — | EP | disclosed |
| US-8906663-B2 | Nitrilases | VERENIUM CORPORATION (US) | 2014-12-09 | — | — | US | disclosed |
| EP-1576108-A2 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | DIVERSA CORPORATION (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050153417-A1 | Halohydrin dehalogenases and related polynucleotides | CODEXIS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050154224-A1 | Continuous process for the cyanation of hydrogenated beta-ketoesters | PHOENIX CHEMICALS LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1506161-A1 | CONTINUOUS PROCESS FOR THE CYANATION OF HYDROGENATED BETA-KETOESTERS | Phoenix Chemicals Limited (GB) | 2005-02-16 | — | — | EP | disclosed |
| US-20040014195-A1 | Nitrilases, nucleic acids encoding them and methods for making and using them | DIVERSA CORPORATION (US) | 2004-01-22 | — | — | US | disclosed |
| US-20040002147-A1 | Nitrilases | DIVERSA CORPORATION | 2004-01-01 | — | — | US | disclosed |
| WO-2003097810-A2 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | DIVERSA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003097581-A1 | CONTINUOUS PROCESS FOR THE CYANATION OF HYDROGENATED BETA-KETOESTERS | PHOENIX CHEMICALS LIMITED (GB) | 2003-11-27 | — | — | WO | disclosed |
| US-20030124698-A1 | Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia | DIVERSA CORPORATION | 2003-07-03 | — | — | US | disclosed |
| WO-2003000840-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014195-A1 | Nitrilases, nucleic acids encoding them and methods for making and using them | RNGTT, NSUN2, NSUN3 | TDP1 34/4885CHRM1 4706/4885AKR1A1 1255/4885 |
| US-20040002147-A1 | Nitrilases | RNGTT, DNTT, NOP2 | TDP1 49/4885CHRM1 4247/4885AKR1A1 1186/4885 |
| US-20030124698-A1 | Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia | NIT2, DNPH1, ASNS | TDP1 328/4885CHRM1 3255/4885AKR1A1 776/4885 |
| US-20050154224-A1 | Continuous process for the cyanation of hydrogenated beta-ketoesters | KHK, BCKDK, CYP51A1 | TDP1 3184/4885CHRM1 3893/4885AKR1A1 403/4885 |
| US-20050153417-A1 | Halohydrin dehalogenases and related polynucleotides | HDHD5, DERA, VNN1 | TDP1 534/4885CHRM1 4732/4885AKR1A1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.